Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Collaring Wolfe: Propoxyphene Moves Activist Back To Public Supplicant Role

Executive Summary

For almost four decades, one of the most painful public relations challenges for drug companies has been the need to respond quickly to surprise petitions from Public Citizen's Health Research Group asking FDA to withdraw a drug for an alleged safety issue

You may also be interested in...



Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote

Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.

Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role

FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA

Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role

FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel